Pan KRas-IN-1

Modify Date: 2025-08-23 19:00:37

Pan KRas-IN-1 Structure
Pan KRas-IN-1 structure
Common Name Pan KRas-IN-1
CAS Number 2791263-84-6 Molecular Weight 607.67
Density N/A Boiling Point N/A
Molecular Formula C33H36F3N5O3 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Pan KRas-IN-1


Pan KRas-IN-1 is a pan KRas inhibitor, can be used for drug resistance in cancer developed with KRas G12C inhibitors[1].

 Names

Name Pan KRas-IN-1

 Pan KRas-IN-1 Biological Activity

Description Pan KRas-IN-1 is a pan KRas inhibitor, can be used for drug resistance in cancer developed with KRas G12C inhibitors[1].
Related Catalog
Target

KRas G12D:9 nM (IC50)

KRas G12S:11 nM (IC50)

KRas G12C:6 nM (IC50)

KRas Q61H:12 mM (IC50)

KRas G12V:29 mM (IC50)

K-Ras WT:32 nM (IC50)

K-Ras G12R:681 nM (IC50)

K-Ras G13D:23 nM (IC50)

In Vitro Pan KRas-IN-1 (example 5) shows high binding capacity to KRas, with IC50s of <2 nM among different KRas isform, including G12D, G12V, G12R, G12A, G12S, G13D, Q61H, and WT[1]. Pan KRas-IN-1 inhibits the phosphorylation of ERK downstream of KRas in different cells; AsPC-1 (G12D, IC50=9 nM), A549 (G12S, IC50=11 nM), HCT116 (G13D, IC50=23 nM), NCI-H358 (G12C, IC50=6 nM), NCI-H460 (Q61H, IC50=12 nM), NCI-H727 (G12V, IC50=29 nM), MKN1 (WT, IC50=32 nM), PSN-1 (G12R, IC50=681 nM)[1]. Pan KRas-IN-1 (0-3000 nM; 5 d) exhibits anti-proliferative activity against mutation of reststance to Adagrasib (HY-130149, MRTX849) in mouse 3T3 fibroblasts, with IC50s of 32 nM (G12A), 28.1 nM (G12C), 20.25 nM (G12D), 1742 nM (G12R), 94 nM (G12V), 50 nM (G12W), 610 nM (G13D), 58 nM (Q61H)[1].
References

[1]. Wang Xiaolun, et al. Preparation of azaquinazoline pan-KRas inhibitors: World Intellectual Property Organization, WO2022132200[P]. 2022-06-23.

 Chemical & Physical Properties

Molecular Formula C33H36F3N5O3
Molecular Weight 607.67
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.